GRDN Government Contracts & Federal Awards (2026)

GRDN executive trading overview and key direct answers

Corporate leadership at Guardian Pharmacy Services, Inc. (GRDN) reported 10 open-market transactions on SEC Form 4 across the trailing twelve-month window through 2026-03-20. Net executive transaction flow reflects net sellers by $419.12M, comprised of 1 open-market purchases worth $99.8K against 9 open-market dispositions totaling $419.22M. Such disclosures serve as a primary foundation for evaluating insider capital commitments within public Retail-Drug Stores and Proprietary Stores enterprises. Statutory disclosure obligations require public company leadership to file transaction documentation without delay, granting institutional observers immediate insight into executive ownership trajectories. Institutional market participants evaluate corporate governance disclosures alongside primary market fundamentals to gauge leadership alignment.

GRDN insider buying and selling over the past year

Over the past year Guardian Pharmacy Services, Inc. insiders filed 10 open-market Form 4 trades — 1 purchases worth $99.8K and 9 sales worth $419.22M — which makes them net sellers by $419.12M.

None of the 9 sales were flagged as Rule 10b5-1 plan trades, meaning each one was a discretionary decision at the time of filing. Activity clustered in 2026-03 (9 trades) and 2025-12 (1 trades); the latest filing in this window is dated 2026-03-20. Classification telemetry shows 10 tactical transactions compared to 0 recurring corporate routine trades. The single largest trade was a sale of 3,570,677 shares worth $105.98M on 2026-03-20.

GRDN insider cost basis and market valuation scenarios

Evaluating insider pricing realizations against closing equity values provides fundamental context on whether leadership dispositions coincided with peak valuation multiples or routine treasury operations. Liquidity parameters across secondary venues ensure that corporate ownership distributions for Guardian Pharmacy Services, Inc. clear orderly alongside routine institutional market turnover.

Congressional trading disclosures for GRDN

Public disclosures under the STOCK Act of 2012 indicate no active trading records in Guardian Pharmacy Services, Inc. (GRDN) by members of Congress over recent observation windows. This absence confirms that Capitol Hill lawmakers held no disclosed personal transactions in the security during recent regulatory periods.

Guardian Pharmacy Services, Inc. federal procurement profile

Federal prime award repositories record no ongoing contract obligations with Guardian Pharmacy Services, Inc., indicating that commercial market transactions generate the enterprise revenue stream.

Sources and method

All numerical indicators presented in this dossier are calculated strictly from primary regulatory filings in Gemral Edge. Insider statistics evaluate exclusively open-market Form 4 purchases and dispositions, filtering out equity grants, option conversions, and tax withholdings.

• SEC EDGAR Form 4 (edge_insider_trades, codes P/S open-market only) — as of 2026-03-20

GRDN data questions

Are GRDN insiders buying or selling stock?

Over the past year Guardian Pharmacy Services, Inc. insiders filed 10 open-market Form 4 trades — 1 purchases worth $99.8K and 9 sales worth $419.22M — which makes them net sellers by $419.12M.

Has any member of Congress traded GRDN stock?

No. Congressional records under the STOCK Act of 2012 show zero disclosed trades for GRDN over the monitored period.